- Home
- TKLF vs NERV Comparison
TKLF vs NERV Comparison
Compare TKLF & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- NERV
- Stock Information
- Founded
- TKLF 2006
- NERV 2007
- Country
- TKLF Japan
- NERV United States
- Employees
- TKLF N/A
- NERV N/A
- Industry
- TKLF Other Specialty Stores
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- NERV Health Care
- Exchange
- TKLF Nasdaq
- NERV Nasdaq
- Market Cap
- TKLF 15.6M
- NERV 14.6M
- IPO Year
- TKLF 2022
- NERV 2014
- Fundamental
- Price
- TKLF N/A
- NERV $2.83
- Analyst Decision
- TKLF
- NERV Hold
- Analyst Count
- TKLF 0
- NERV 1
- Target Price
- TKLF N/A
- NERV $5.00
- AVG Volume (30 Days)
- TKLF 20.7K
- NERV 639.5K
- Earning Date
- TKLF 07-10-2025
- NERV 11-04-2025
- Dividend Yield
- TKLF N/A
- NERV N/A
- EPS Growth
- TKLF N/A
- NERV N/A
- EPS
- TKLF 1.57
- NERV 1.48
- Revenue
- TKLF $210,119,238.00
- NERV N/A
- Revenue This Year
- TKLF N/A
- NERV N/A
- Revenue Next Year
- TKLF N/A
- NERV N/A
- P/E Ratio
- TKLF $2.34
- NERV $1.47
- Revenue Growth
- TKLF 7.38
- NERV N/A
- 52 Week Low
- TKLF $2.20
- NERV $1.15
- 52 Week High
- TKLF $5.80
- NERV $3.29
- Technical
- Relative Strength Index (RSI)
- TKLF 47.73
- NERV 70.41
- Support Level
- TKLF $3.56
- NERV $2.06
- Resistance Level
- TKLF $3.74
- NERV $2.15
- Average True Range (ATR)
- TKLF 0.20
- NERV 0.11
- MACD
- TKLF -0.01
- NERV 0.02
- Stochastic Oscillator
- TKLF 32.87
- NERV 70.72
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.